Jefferies Keeps a Hold Rating on Bristol Myers

By Austin Angelo

In a report released today, Ian Hilliker from Jefferies reiterated a Hold rating on Bristol Myers (NYSE: BMY), with a price target of $66. The company’s shares closed yesterday at $58.84.

According to, Hilliker is a 1-star analyst with an average return of -1.7% and a 50.0% success rate. Hilliker covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Merck & Company, and Eli Lilly & Co.

Bristol Myers has an analyst consensus of Moderate Buy, with a price target consensus of $68.29.

Based on Bristol Myers’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $5.45 billion and GAAP net loss of $2.33 billion. In comparison, last year the company earned revenue of $4.93 billion and had a net profit of $1.57 billion.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.